ArticleJournal of translational medicine2026
Exosome-mediated hepatocellular carcinoma progression by modulating macrophage metabolic reprogramming and macrophage M2 polarization via exosome-derived hsa_circ_0057320-miR-28-5p/E2F6 axis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exosomal circular RNAs in the tumor immune microenvironment: From regulatory mechanisms to therapeutic opportunities and translational hurdles (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHepatocellular carcinoma is an aggressive malignancy with poor outcomes. Emerging studies highlight the importance of the tumor microenvironment in HCC progression, where exosomes serve as critical messengers linking tumor cells with surrounding stromal components. Although circRNAs are abundantly present in tumor-derived exosomes, their precise roles and mechanisms in HCC remain poorly defined.
methodsExosomes were characterized using transmission electron microscopy and flow cytometry. Differentially expressed circRNAs were identified by RNA sequencing. Macrophage polarization and metabolic reprogramming were evaluated by western blotting, immunofluorescence and metabolomics. The role of hsa_circ_0057320, miR-28-5p, and E2F6 in HCC progression was examined through transwell, tube formation, and spheroid-sprouting assays. Xenograft mouse models were constructed to verify the role of them in metastasis and angiogenesis, exosomes in progression of HCC. Interactions among hsa_circ_0057320, miR-28-5p, and E2F6 were explored using RIP and dual-luciferase reporter assays.
resultsIn this study, we found that exosomes derived from HOXD3-treated HCCs induced macrophage polarization toward the M2 phenotype via metabolic reprogramming. In addition, HOXD3-stimulated HCC cells secreted exosomes enriched in hsa_circ_0057320, which induce the alternatively activated (M2) macrophage phenotype and enhanced angiogenesis and metastatic capability in vivo and vitro. The role of hsa_circ_0057320 in the metastasis and invasion of HCC was reversed after the enhance of miR-28-5p. E2F6, a target of miR-28-5p, was markedly upregulated in HCC tissues and cells. Additionally, a positive relationship was established between hsa_circ_0057320 and E2F6, contrasting with a negative association with miR-28-5p.
conclusionsExosomes derived from HOXD3-induced HCC cells promotes M2 macrophage polarization via metabolic reprogramming. In addition, HOXD3-induced exosomal hsa_circ_0057320 promotes macrophage M2 polarization via the miR-28-5p/E2F6 axis, thereby accelerating HCC malignancy. These findings reveal the interactive communication mechanism between HCCs and TME, and highlight hsa_circ_0057320 as a potential exosomal indicator and therapeutic target for metastatic HCC.
Indexed as
Identifiers
42458526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.